Amneal Pharmaceuticals (AMRX) Competitors

Ascendis Pharma A/S (NASDAQ:ASND) and Amneal Pharmaceuticals (NASDAQ:AMRX) are both mid-cap medical companies, but which is the better business? We will contrast the two companies based on the strength of their media sentiment, risk, profitability, earnings, dividends, analyst recommendations, community ranking, valuation and institutional ownership.

Do insiders & institutionals believe in ASND or AMRX?

31.8% of Amneal Pharmaceuticals shares are owned by institutional investors. 40.0% of Ascendis Pharma A/S shares are owned by insiders. Comparatively, 26.6% of Amneal Pharmaceuticals shares are owned by insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a company is poised for long-term growth.

Which has better valuation & earnings, ASND or AMRX?

Amneal Pharmaceuticals has higher revenue and earnings than Ascendis Pharma A/S. Ascendis Pharma A/S is trading at a lower price-to-earnings ratio than Amneal Pharmaceuticals, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Ascendis Pharma A/S	$363.64M	25.81	-$409.12M	-$7.10	-21.68
Amneal Pharmaceuticals	$2.79B	0.79	-$83.99M	-$0.38	-18.82

Is ASND or AMRX more profitable?

Amneal Pharmaceuticals has a net margin of -6.88% compared to Ascendis Pharma A/S's net margin of -104.54%. Ascendis Pharma A/S's return on equity of 0.00% beat Amneal Pharmaceuticals' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Ascendis Pharma A/S	-104.54%	N/A	-39.23%
Amneal Pharmaceuticals	-6.88%	-346.26%	4.85%

Do analysts recommend ASND or AMRX?

Ascendis Pharma A/S currently has a consensus price target of $204.64, suggesting a potential upside of 32.95%. Amneal Pharmaceuticals has a consensus price target of $10.80, suggesting a potential upside of 51.05%. Given Amneal Pharmaceuticals' stronger consensus rating and higher possible upside, analysts plainly believe Amneal Pharmaceuticals is more favorable than Ascendis Pharma A/S.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Ascendis Pharma A/S	0 Sell rating(s)	1 Hold rating(s)	13 Buy rating(s)	0 Strong Buy rating(s)	2.93
Amneal Pharmaceuticals	0 Sell rating(s)	0 Hold rating(s)	5 Buy rating(s)	0 Strong Buy rating(s)	3.00

Does the MarketBeat Community believe in ASND or AMRX?

Ascendis Pharma A/S received 429 more outperform votes than Amneal Pharmaceuticals when rated by MarketBeat users. However, 94.74% of users gave Amneal Pharmaceuticals an outperform vote while only 66.82% of users gave Ascendis Pharma A/S an outperform vote.

Company	Underperform	Outperform
Ascendis Pharma A/S	Outperform Votes 447 66.82%	Underperform Votes 222 33.18%
Amneal Pharmaceuticals	Outperform Votes 18 94.74%	Underperform Votes 1 5.26%

Which has more risk and volatility, ASND or AMRX?

Ascendis Pharma A/S has a beta of 0.54, meaning that its stock price is 46% less volatile than the S&P 500. Comparatively, Amneal Pharmaceuticals has a beta of 1.06, meaning that its stock price is 6% more volatile than the S&P 500.

Does the media refer more to ASND or AMRX?

In the previous week, Ascendis Pharma A/S had 5 more articles in the media than Amneal Pharmaceuticals. MarketBeat recorded 11 mentions for Ascendis Pharma A/S and 6 mentions for Amneal Pharmaceuticals. Ascendis Pharma A/S's average media sentiment score of 1.50 beat Amneal Pharmaceuticals' score of 1.08 indicating that Ascendis Pharma A/S is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Ascendis Pharma A/S	8 Very Positive mention(s)	1 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Amneal Pharmaceuticals	3 Very Positive mention(s)	1 Positive mention(s)	0 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Summary

Amneal Pharmaceuticals beats Ascendis Pharma A/S on 11 of the 18 factors compared between the two stocks.